Monte Rosa Therapeutics, Inc. Weighted Average Number of Shares Outstanding, Basic and Diluted
Monte Rosa Therapeutics, Inc. (GLUE) reported Weighted Average Number of Shares Outstanding, Basic and Diluted of 46.60 million shares for the 3-month period ending 2022-03-31, per its 10-Q filed 2022-05-11.
Discontinued › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted · last filed 2022-05-11
- Monte Rosa Therapeutics, Inc. weighted average number of shares outstanding, basic and diluted for the quarter ending 2022-03-31 was 46.60M shares, a 2626.13% increase year-over-year.
- Monte Rosa Therapeutics, Inc. weighted average number of shares outstanding, basic and diluted for the quarter ending 2021-12-31 was 46.75M shares, a 2740.83% increase year-over-year.
- Monte Rosa Therapeutics, Inc. weighted average number of shares outstanding, basic and diluted for the quarter ending 2021-09-30 was 45.99M shares, a 2905.98% increase year-over-year.
- Monte Rosa Therapeutics, Inc. weighted average number of shares outstanding, basic and diluted for the quarter ending 2021-06-30 was 5.07M shares, a 243.67% increase year-over-year.
- Monte Rosa Therapeutics, Inc. weighted average number of shares outstanding, basic and diluted for fiscal 2021 was 25.00M shares, a 1548.09% increase from fiscal 2020.
- Monte Rosa Therapeutics, Inc. weighted average number of shares outstanding, basic and diluted for fiscal 2020 was 1.52M shares.
| Period end | Weighted Average Number of Shares Outstanding, Basic and Diluted 3 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 6 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 9 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 12 month |
|---|---|---|---|---|
| 2022-03-31 | 46.60M shares 10-Q · filed 2022-05-11 | 46.67M shares derived: average of 2 quarters · filed 2022-05-11 | 46.44M shares derived: average of 3 quarters · filed 2022-05-11 | 36.10M shares derived: average of 4 quarters · filed 2022-05-11 |
| 2021-12-31 | 46.75M shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-29 | 46.37M shares derived: average of 2 quarters · filed 2022-03-29 | 32.60M shares derived: average of 3 quarters · filed 2022-03-29 | 25.00M shares 10-K · filed 2022-03-29 |
| 2021-09-30 | 45.99M shares 10-Q · filed 2021-11-10 | 25.53M shares derived: average of 2 quarters · filed 2021-11-10 | 17.75M shares 10-Q · filed 2021-11-10 | 13.60M shares derived: average of 4 quarters · filed 2022-05-11 |
| 2021-06-30 | 5.07M shares 10-Q · filed 2021-08-12 | 3.40M shares 10-Q · filed 2021-08-12 | 2.81M shares derived: average of 3 quarters · filed 2022-05-11 | 2.49M shares derived: average of 4 quarters · filed 2022-05-11 |
| 2021-03-31 | 1.71M shares 10-Q · filed 2022-05-11 | 1.68M shares derived: average of 2 quarters · filed 2022-05-11 | 1.63M shares derived: average of 3 quarters · filed 2022-05-11 | 1.59M shares derived: average of 4 quarters · filed 2022-05-11 |
| 2020-12-31 | 1.65M shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-29 | 1.59M shares derived: average of 2 quarters · filed 2022-03-29 | 1.55M shares derived: average of 3 quarters · filed 2022-03-29 | 1.52M shares 10-K · filed 2022-03-29 |
| 2020-09-30 | 1.53M shares 10-Q · filed 2021-11-10 | 1.50M shares derived: average of 2 quarters · filed 2021-11-10 | 1.47M shares 10-Q · filed 2021-11-10 | |
| 2020-06-30 | 1.48M shares 10-Q · filed 2021-08-12 | 1.45M shares 10-Q · filed 2021-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |